FBL8 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Velcade (Bortezomib) is a proteasome inhibitor that can functionally inhibit FBL8 by preventing the degradation of regulatory proteins that interact with FBL8, leading to an accumulation of these proteins and a subsequent decrease in FBL8 activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is another proteasome inhibitor that can lead to the functional inhibition of FBL8 by causing an accumulation of regulatory proteins that govern the activity of FBL8. This accumulation can negatively affect FBL8's function by disrupting its normal regulatory processes. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib, as a proteasome inhibitor, can functionally inhibit FBL8 through the accumulation of upstream regulatory proteins that are responsible for controlling the activity of FBL8, potentially leading to the inhibition of its function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin selectively inhibits the proteasome, which can lead to the functional inhibition of FBL8 by causing the accumulation of proteins that interact with FBL8, disrupting its activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor that can inhibit FBL8 function by preventing the degradation of proteins that regulate the activity of FBL8, causing an accumulation that affects FBL8's function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can indirectly inhibit FBL8 by stabilizing proteins that control FBL8 activity, leading to a reduction in its functional activity. | ||||||
Aclacinomycin A | 57576-44-0 | sc-200160 | 5 mg | $132.00 | 10 | |
Aclacinomycin, though primarily an antibiotic, can inhibit the proteasome and would therefore stabilize proteins that regulate FBL8, leading to a decrease in FBL8 activity. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A can inhibit FBL8 by interfering with the proteasomal pathway, leading to the accumulation of proteins that regulate FBL8 and thus inhibiting its activity. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that can inhibit FBL8 by preventing the degradation of proteins that regulate FBL8 activity, leading to an accumulation of these proteins and a subsequent decrease in FBL8 function. | ||||||